- Organizations: Innovent Biologics
Pipeline
Innovent's Sycume meets phase 3 endpoint for inactive TED
RESTORE-3 trial demonstrates efficacy in reducing proptosis and a favorable safety profile for patients with inactive TED.Pipeline
Innovent Biologics' wet AMD anti-VEGF meets phase 2 primary endpoint
Intravitreal injection of high-dose IBI302 demonstrates positive long-interval dosing efficacy and safety data.Pipeline